See more : Abraxas Petroleum Corporation (AXAS) Income Statement Analysis – Financial Results
Complete financial analysis of IO Biotech, Inc. (IOBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IO Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Central Sports Co., Ltd. (4801.T) Income Statement Analysis – Financial Results
- Angel Pond Holdings Corporation (POND-UN) Income Statement Analysis – Financial Results
- Avance Gas Holding Ltd (AGAS.OL) Income Statement Analysis – Financial Results
- Norben Tea & Exports Limited (NORBTEAEXP.NS) Income Statement Analysis – Financial Results
- EHAVE, Inc. (EHVVF) Income Statement Analysis – Financial Results
IO Biotech, Inc. (IOBT)
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.00K | 540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -756.00K | -540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.83M | 46.99M | 30.15M | 8.46M | 7.94M |
| General & Administrative | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Other Expenses | 0.00 | 0.00 | -26.54M | -1.99M | -781.00K |
| Operating Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Cost & Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Interest Income | 5.88M | 1.41M | 361.00 | 26.00 | 6.00 |
| Interest Expense | 0.00 | 302.00K | 361.00K | 26.00K | 6.00K |
| Depreciation & Amortization | 215.00K | 540.00K | 2.00K | 10.15M | 9.91M |
| EBITDA | -91.44M | -69.34M | -67.45M | 0.00 | -824.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -91.44M | -71.42M | -41.23M | -10.15M | -9.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 1.24M | -26.58M | -1.90M | -830.00K |
| Income Before Tax | -85.23M | -70.19M | -67.81M | -12.04M | -10.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 852.00K | 1.27M | 68.00K | 26.00K | 6.00K |
| Net Income | -86.08M | -71.46M | -67.88M | -12.07M | -10.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| EPS Diluted | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
| Weighted Avg Shares Out (Dil) | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first...
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in...
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda ® demonstrated promising activity with an overall response rate of 55% unconfirmed/48% confirmed, disease control rate of 81%, and approximately...
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed --
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected...
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will provide a corporate...
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced...
3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts
Penny stocks are a fascinating category of investment opportunities.
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that an abstract related to IO102-IO103, the company's lead investigational therapeutic...
Source: https://incomestatements.info
Category: Stock Reports